ANU Stock Chart & Stats
€1.79
€0.09(5.04%)
At close: 4:00 PM EDT
€1.79
€0.09(5.04%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
Volume0.00
Average Volume (3M)213.00
Market Cap
€3.19M
Enterprise Value€3.22
Total Cash (Recent Filing)€250.45K
Total Debt (Recent Filing)€15.07K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,816,565
10 Day Avg. Volume640
30 Day Avg. Volume213
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low reported debt (TTM total debt ~15k; debt-to-equity ~0.02) materially reduces bankruptcy and interest-rate risk, giving management flexibility to fund near-term clinical programs via equity or partnerships without heavy fixed-cost debt servicing, a durable financial buffer.
Improving Loss TrajectoryThe company has meaningfully reduced operating losses (EBIT improved from ~12.43M in 2022 to ~3.10M TTM), indicating durable operational tightening and cost discipline in R&D and overhead that, if sustained, lowers future financing needs and improves runway visibility for development milestones.
Focused Clinical-stage PipelineA clear, specialized focus on small-molecule therapeutics for kidney and metabolic disorders concentrates R&D efforts, supports targeted regulatory and clinical strategy, and creates potential for program-level value realization or partnerships; specialization aids competitive positioning in a defined niche.
Bears Say
No Product RevenueThe company reports no recurring product revenue and sustained net losses (TTM net loss ~2.75M; 2024 net loss ~4.54M), meaning operations depend on external capital. Lack of revenue undermines self-sufficiency and heightens execution risk over intermediate horizons absent successful partnerships or approvals.
Persistent Cash BurnConsistent negative operating and free cash flow (TTM OCF ~-2.62M; FCF ~-2.15M) and a recent decline in free cash flow indicate ongoing funding needs. This persistent burn creates recurring financing dependence and dilutive equity raises unless clinical progress materially de-risks commercial prospects or reduces spend.
Shrinking Equity BaseMaterial reduction in shareholders' equity (from ~13.20M in 2021 to ~1.28M TTM) signals cumulative losses and dilution, weakening the capital cushion. A thinner equity base limits balance-sheet resilience, increases sensitivity to further financing, and raises governance and investor-concentration risks over the medium term.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €3.19M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 5 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -€0.502 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -€0.502 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.